This paper is only available as a PDF. To read, Please Download here.
The effect of ciprofibrate, 2[p-(2,2-dichlorocyclopropyl)-phenoxyl]-2-methyl propionic acid, in daily doses of 50, 100 and 200 mg was studied in 50 patients with hyperlipoproteinaemia (21 type IIA, 10 type IIB and 19 type IV). Ciprofibrate was convenient to take and was without subjective side effects. The greatest hypolipidaemic effects were reached for all lipoproteins with 200 mg daily. In type IIA and IIB, mean low density lipoprotein (LDL) cholesterol was normalized on the 200 mg dose. The effect was highly dependent on initial LDL cholesterol concentrations, decreases being observed above 4 mmol/1 and increases below that concentration. Mean very low density lipoprotein (VLDL) triglyceride concentrations decreased on 200 mg per day by 48–59%. HDL cholesterol increased in all types of hyperlipoproteinaemia by 6–19%, the change being unrelated to changes in VLDL lipids. With a dosage of 200 mg daily the effects were maintained for the following period of 6 months. It is concluded from this study that it would be appropriate to start patients on 100 mg daily and then titrate their dose according to response. The optimal dosage for ciprofibrate seems to be 200 mg daily.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The results of animal studies with ciprofibrate a new orally effective hypolipidemic drug.Atherosclerosis. 1979; 32: 155
- Lipoprotein fractionation.J. Clin. Path. 1973; 26: 32
- Ass. Clin. Path. 1973; 5 (Suppl.)
- A new method for the direct determination of serum cholesterol.J. Lab. Clin. Med. 1953; 41: 486
- A colorimetric method for estimating serum triglycerides.Clin. Chim. Acta. 1968; 22: 393
- Classification of hyperlipidaemias and hyperlipoproteinaemias.Bull. Wld Hlth Org. 1970; 43: 891
- Statistical Methods.Iowa State University Press, Ames, IA1961
- Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.Atherosclerosis. 1978; 31: 421
- Effect of hypolipidemic drugs on serum lipoproteins.Progr. Biochem. Pharmacol. 1979; 15: 238
- Studies on serum lipoproteins and lipid metabolism—Analysis of a random sample of 40 year old men.Acta Med. Scand. 1980;
- One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia,.Atherosclerosis. 1978; 31: 429
- The relation between plasma fibrinogen, blood hematocrit and exercise at segment depressions in hyperlipoproteinemia.Artery. 1980; 7: 215
- Effect of blood viscosity decrease on exercise at segment depressions in hyperlipidemia.Artery. 1980; 7: 206
Accepted: October 13, 1981
Received in revised form: October 12, 1981
Received: April 23, 1981
☆Supported by grants from the Swedish Medical Research Council No. 19X-204.
© 1982 Published by Elsevier Inc.